Advertisement

Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk

Decades Later, Any New Lessons Learned?

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Turesson C.
        • Jacobsson L.T.H.
        • Matteson E.L.
        Cardiovascular co-morbidity in rheumatic diseases.
        Vasc Health Risk Manag. 2008; 4: 605-614
        • Marcus A.J.
        • Broekman M.J.
        • Pinsky D.J.
        COX inhibitors and thromboregulation.
        N Engl J Med. 2002; 347 (Available at:): 1025-1026https://doi.org/10.1056/NEJMcibr021805
        • Yan C.
        • AS C.
        • Bianca R.
        • et al.
        Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2.
        Science (80- ). 2002; 296 (Available at:): 539-541https://doi.org/10.1126/science.1068711
        • Kim G.H.
        Renal effects of prostaglandins and cyclooxygenase-2 inhibitors.
        Electrolyte Blood Press. 2008; 6: 35-41
        • Houston M.C.
        Nonsteroidal anti-inflammatory drugs and antihypertensives.
        Am J Med. 1991; 90: S42-S47
        • Fisher N.D.L.
        • Hurwitz S.
        • Ferri C.
        • et al.
        Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension.
        Hypertension. 1999; 34: 388-394
        • Schmidt M.
        • Sørensen H.T.
        • Pedersen L.
        Diclofenac use and cardiovascular risks: Series of nationwide cohort studies.
        BMJ. 2018; : 362
        • Patrono C.
        • Patrignani P.
        • Rodríguez L.A.G.
        Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
        J Clin Invest. 2001; 108: 7-13
        • Sciulli M.G.
        • Capone M.L.
        • Tacconelli S.
        • et al.
        The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
        Pharmacol Rep. 2005; 57: 66
        • BOMBARDIER C.
        • LAINE L.
        • REICIN A.
        • et al.
        Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
        N Engl J Med. 2000; 343: 1520-1528
        • Baron J.A.
        • Sandler R.S.
        • Bresalier R.S.
        • et al.
        Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.
        Lancet. 2008; 372 (Available at:): 1756-1764https://doi.org/10.1016/S0140-6736(08)61490-7
        • Choi H.
        • Seeger J.
        • Kuntz K.
        Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
        Am J Med. 2004; 116: 621-629
        • Kearney P.M.
        • Baigent C.
        • Godwin J.
        • et al.
        Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
        Br Med J. 2006; 332: 1302-1305
        • Silverstein F.
        • Faich G.
        • Goldstein J.L.
        • et al.
        Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis The CLASS Study: A Randomized Controlled Trial.
        JAMA. 2000; 284: 1247-1255
        • Cannon C.P.
        • Curtis S.P.
        • FitzGerald G.A.
        • et al.
        Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
        Lancet. 2006; 368: 1771-1781
        • Bhala N.
        • Emberson J.
        • Merhi A.
        • et al.
        Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
        Lancet (London, England). 2013; 382: 769-779
        • Macdonald T.M.
        • Hawkey C.J.
        • Ford I.
        • et al.
        Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: The Standard care vs. Celecoxib Outcome Trial (SCOT).
        Eur Heart J. 2017; 38: 1843-1850
        • Nissen S.E.
        • Yeomans N.D.
        • Solomon D.H.
        • et al.
        Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
        N Engl J Med. 2016; 375: 2519-2529
        • Gislason G.H.
        • Jacobsen S.
        • Rasmussen J.N.
        • et al.
        Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
        Circulation. 2006; 113: 2906-2913
        • Schjerning Olsen A.-M.
        • Fosbøl E.L.
        • Lindhardsen J.
        • et al.
        Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
        Circulation. 2011; 123: 2226-2235
        • Olsen A.-M.S.
        • Fosbøl E.L.
        • Lindhardsen J.
        • et al.
        Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study.
        Circulation. 2012; 126: 1955-1963
        • Gislason G.H.
        • Rasmussen J.N.
        • Abildstrom S.Z.
        • et al.
        Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.
        Arch Intern Med. 2009; 169: 141-149
        • Fosbøl E.L.
        • Gislason G.H.
        • Jacobsen S.
        • et al.
        Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study.
        Clin Pharmacol Ther. 2009; 85: 190-197
        • Barcella C.A.
        • Lamberts M.
        • McGettigan P.
        • et al.
        Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—A nationwide study in patients with osteoarthritis.
        Basic Clin Pharmacol Toxicol. 2019; 124: 629-641
        • Sondergaard K.B.
        • Weeke P.
        • Wissenberg M.
        • et al.
        Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.
        Eur Hear Journal Cardiovasc Pharmacother. 2017; 3: 100-107
        • Bally M.
        • Dendukuri N.
        • Rich B.
        • et al.
        Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data.
        BMJ. 2017; 357
        • Gladding P.A.
        • Webster M.W.I.
        • Farrell H.B.
        • et al.
        The Antiplatelet Effect of Six Non-Steroidal Anti-Inflammatory Drugs and Their Pharmacodynamic Interaction With Aspirin in Healthy Volunteers.
        Am J Cardiol. 2008; 101: 1060-1063
        • Reed G.W.
        • Abdallah M.S.
        • Shao M.
        • et al.
        Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.
        J Am Coll Cardiol. 2018; 71: 1741-1751
        • Chan F.K.L.
        • Lanas A.
        • Scheiman J.
        • et al.
        Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
        Lancet (London, England). 2010; 376: 173-179
        • Atzeni F.
        • Rodríguez-Carrio J.
        • Popa C.D.
        • et al.
        Cardiovascular effects of approved drugs for rheumatoid arthritis.
        Nat Rev Rheumatol. 2021; 17: 270-290
        • Choi H.K.
        • Hernán M.A.
        • Seeger J.D.
        • et al.
        Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study.
        Lancet. 2002; 359: 1173-1177
        • Xie W.
        • Yang X.
        • Ji L.L.
        • et al.
        Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis.
        Semin Arthritis Rheum. 2020; 50: 598-607
        • Roubille C.
        • Richer V.
        • Starnino T.
        • et al.
        The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.
        Ann Rheum Dis. 2015; 74: 480-489
        • US Food and Drug Administration
        FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet].
        (Available at:)
        • Krebs E.E.
        • Gravely A.
        • Nugent S.
        • et al.
        Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain the SPACE randomized clinical trial.
        JAMA. 2018; 319: 872-882
        • Singleton J.H.
        • Abner E.L.
        • Akpunonu P.D.
        • et al.
        Association of nonacute opioid use and cardiovascular diseases: a scoping review of the literature.
        J Am Heart Assoc. 2021; 10: e021260
        • Feng Y.
        • He X.
        • Yang Y.
        • et al.
        Current research on opioid receptor function.
        Curr Drug Targets. 2012; 13: 230-246
        • Zobdeh F.
        • Eremenko II,
        • Akan M.A.
        • et al.
        Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review.
        Pharmaceutics. 2022; 14: 1190
        • Cao Y.
        • Noori M.
        • Nazari M.
        • et al.
        Molecular docking evaluation of celecoxib on the boron nitride nanostructures for alleviation of cardiovascular risk and inflammatory.
        Arab J Chem. 2022; 15 (Available at:): 103521https://doi.org/10.1016/j.arabjc.2021.103521
        • Öztürk İ.B.
        • Garip Y.
        • Sivas F.
        • et al.
        Kinesiophobia in rheumatoid arthritis patients: Relationship with quadriceps muscle strength, fear of falling, functional status, disease activity, and quality of life.
        Arch Rheumatol. 2021; 36: 427-434
        • Ho K.Y.
        • Cardosa M.S.
        • Chaiamnuay S.
        • et al.
        Practice advisory on the appropriate use of NSAIDs in primary care.
        J Pain Res. 2020; 13: 1925-1939